This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ehmann, T. S. Articles by Macewan, G. W. Search for Related Content PubMed PubMed Citation Articles by Ehmann, T. S. Articles by Macewan, G. W. Social Bookmarking                         What's this?

Outcome Measurement in Pharmacological Trials: Validity of the Routine Assessment of Patient Progress (RAPP)

Department of Psychiatry, St Vincent’s Hospital, Vancouver, Canadatomse{at}telus.net

T. Kragelj

E. Higgs

S. W. Flynn

S. Altman

Refractory Psychosis Program, Riverview Hospital, Port Coquitlam, Canada

G. N. Smith

W. G. Honer

G. W. Macewan

Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

The assessment of outcomes after treatment with antipsychotic medication is fundamental to clinical care and research. The Routine Assessment of Patient Progress (RAPP) is a reliable multidimensional scale that employs nurses’ ratings of symptoms and functioning in psychiatric inpatients. The present study sought to extend validity evidence for the RAPP by examining its ability to reflect changes associated with treatment by antipsychotic medications. The use of a different sample in this study also provided the opportunity to replicate earlier validity data collected on the original set of patients. Ninety-seven separate trials were conducted, involving 65 consecutive admissions to a unit that specializes in the assessment and treatment of patients with long standing severe psychiatric disorders. The RAPP, along with the Positive and Negative Syndrome Scale and global measures of severity, were administered at baseline and at the end of each trial. Both factor scores and clinically-derived subscales were analysed for sensitivity to change. Patients were globally rated as improved, unchanged or worsened at the end of the medication trial. Results indicated that the RAPP factor, clinical scale and total scores compared favourably to other outcome measures in patients rated as improved or worse. In patients rated as unchanged, RAPP scores displayed significantly less change than did the PANSS scores. These findings support the validity of the RAPP as an outcome measure in treatment trials.

Key Words: antipsychotic agents/therapeutic use • neuropsychological tests • pyschiatric nursing assessment • psychiatric status rating scales • psychosis • schizophrenia diagnosis/therapy • schizophrenic psychology • treatment outcome

Journal of Psychopharmacology, Vol. 17, No. 4, 425-429 (2003)
DOI: 10.1177/0269881103174006


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?